Evidence map›Paper›PMID 41159002›Full record

ArticlePeerJ2025

Molecular epidemiology of carbapenem-resistant

Lu Wang, Wanxian Gong, Jie Zhang, Runan Zhang, Ying Jing, Yuanhong Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lu WangDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Wanxian GongDepartment of Clinical Laboratory, Lu'an People's Hospital (Lu'an Hospital Affiliated to Anhui Medical University), Lu'an, China.
Jie ZhangDepartment of Clinical Laboratory, Lu'an People's Hospital (Lu'an Hospital Affiliated to Anhui Medical University), Lu'an, China.
Runan ZhangDepartment of Clinical Laboratory Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Ying JingDepartment of Clinical Laboratory Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Yuanhong XuDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The emergence of carbapenem-resistant Patients and methods: Between 2018 and 2022, 33 CREc isolates were obtained from 33 patients at a tertiary hospital in the Dabie Mountains region of China. We performed a retrospective clinical analysis of the patients, followed by next-generation sequencing (NGS) and comprehensive bioinformatics analysis of all 33 CREc isolates. Additionally, phenotypic tests for carbapenemase and AmpC-type β-lactamase production were carried out. Results: This study analyzed 33 CREc clinical isolates from a mountainous region hospital in China. The isolates predominantly originated from elderly patients (66.7% aged ≥ 60 years) with comorbidities (75.8%). Phenotypic analysis showed that 97.0% of isolates produced carbapenemases ( Conclusion: This represents the first systematic investigation of CREc epidemiology in this understudied region. Our results demonstrate a high prevalence of carbapenem resistance mediated primarily by

Indexed as

Carbapenem-Resistant EnterobacteriaceaeCarbapenemsEscherichia coliEscherichia coli InfectionsAdultAgedAged, 80 and overAnti-Bacterial Agentsbeta-LactamasesChinaFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMolecular EpidemiologyAnti-Bacterial Agentsbeta-LactamasesCarbapenemsAntibiotic resistanceCarbapenemasesEscherichia coliNext-generation sequencingSequence typeVirulence factors

Identifiers

PMID41159002
PMCPMC12558158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.